Solid Biosciences Inc.
SLDB
$6.57
$0.162.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.77% | 16.77% | 18.58% | 19.83% | 21.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.46% | 38.14% | 51.39% | 56.78% | 44.15% |
| Operating Income | -37.46% | -38.14% | -51.39% | -56.78% | -44.15% |
| Income Before Tax | -37.30% | -39.80% | -63.16% | -69.90% | -54.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.30% | -39.80% | -63.16% | -69.90% | -54.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.30% | -39.80% | -63.16% | -69.90% | -54.77% |
| EBIT | -37.46% | -38.14% | -51.39% | -56.78% | -44.15% |
| EBITDA | -38.79% | -39.52% | -52.88% | -58.84% | -44.85% |
| EPS Basic | 34.93% | 33.41% | 18.08% | 15.20% | 24.08% |
| Normalized Basic EPS | 34.94% | 33.41% | 18.08% | 15.20% | 24.14% |
| EPS Diluted | 34.93% | 33.41% | 18.08% | 15.20% | 24.08% |
| Normalized Diluted EPS | 34.94% | 33.41% | 18.08% | 15.20% | 24.14% |
| Average Basic Shares Outstanding | 105.35% | 114.18% | 111.42% | 104.91% | 95.11% |
| Average Diluted Shares Outstanding | 105.35% | 114.18% | 111.42% | 104.91% | 95.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |